Equities research analysts at Brean Capital assumed coverage on shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

A number of other research firms have also issued reports on PCRX. Jefferies Group reaffirmed a “buy” rating and issued a $60.00 target price (down previously from $74.00) on shares of Pacira Pharmaceuticals in a report on Monday, September 26th. BMO Capital Markets reaffirmed a “sell” rating and issued a $36.00 target price on shares of Pacira Pharmaceuticals in a report on Tuesday, July 19th. Mizuho reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, June 22nd. Wedbush reaffirmed an “outperform” rating and issued a $105.00 target price (down previously from $109.00) on shares of Pacira Pharmaceuticals in a report on Thursday, August 4th. Finally, Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Tuesday, July 26th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $72.83.

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 34.76 on Friday. The company’s 50-day moving average price is $39.05 and its 200-day moving average price is $44.23. The company’s market capitalization is $1.30 billion. Pacira Pharmaceuticals has a 52 week low of $31.08 and a 52 week high of $80.25.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.16. The business had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. Pacira Pharmaceuticals had a positive return on equity of 0.02% and a negative net margin of 4.21%. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.20 EPS. On average, equities analysts forecast that Pacira Pharmaceuticals will post $0.44 EPS for the current fiscal year.

In other news, President James S. Scibetta sold 25,000 shares of Pacira Pharmaceuticals stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.21, for a total value of $1,130,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David M. Stack sold 15,000 shares of Pacira Pharmaceuticals stock in a transaction on Monday, August 15th. The shares were sold at an average price of $45.32, for a total value of $679,800.00. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. boosted its stake in Pacira Pharmaceuticals by 257.2% in the first quarter. Prudential Financial Inc. now owns 13,376 shares of the company’s stock valued at $709,000 after buying an additional 9,631 shares during the period. BlackRock Inc. boosted its stake in shares of Pacira Pharmaceuticals by 122.7% in the first quarter. BlackRock Inc. now owns 2,497 shares of the company’s stock worth $133,000 after buying an additional 1,376 shares during the period. BlackRock Group LTD boosted its stake in shares of Pacira Pharmaceuticals by 17.7% in the first quarter. BlackRock Group LTD now owns 23,054 shares of the company’s stock worth $1,221,000 after buying an additional 3,472 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Pacira Pharmaceuticals by 1.2% in the first quarter. BlackRock Fund Advisors now owns 1,582,234 shares of the company’s stock worth $83,827,000 after buying an additional 18,120 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Pacira Pharmaceuticals by 0.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 908,647 shares of the company’s stock worth $48,140,000 after buying an additional 5,903 shares during the period.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.